CB

Commit Biologics

Add a description for facebook

BioTech

Built from public sources. Run Commit Biologics? Claim this page with your @commitbio.com email.

Overview

In the news · Nov 18, 2026Commit Biologics: €54M ($60M) Seed, led by Ackermans & van Haaren. The Copenhagen biotech is working on cancer and autoimmune therapies. Raised €54 million Seed. Read the funding digest
About

Makes immunotherapies that work without T cells. For cancer and autoimmune diseases, using complement activation.

Commit Biologics is a biotech company developing complement-powered immune engagers, a new class of immunotherapies for oncology and autoimmune diseases. The company's BiCE platform activates the complement system to eliminate diseased cells, offering an alternative to T cell-based therapies that works independently of T cell function and presence.

Problem & Solution

The problem
Existing T cell-based immunotherapies like CAR-T cells and T cell engagers have limitations: they require sufficient functional T cells in patients, depend on direct contact between T cells and diseased cells, and carry risks of cytokine release and immune-related side effects. Additionally, many tissues and tumors are poorly infiltrated by T cells.
The solution
Commit Biologics developed BiCE (Bispecific Complement Engagers), a platform that recruits the complement protein C1q directly to diseased cells, triggering potent complement activation and immune-mediated cell killing independent of T cell function. The BiCE platform maintains the safety, stability and manufacturability of conventional antibodies while enabling a new mechanism for targeted cell elimination.

Fact sheet

Industry
BioTech

Run Commit Biologics? Make this page yours.

Claim it with your @commitbio.com email, fix what we got wrong, and share one clean link with investors and customers.

Claim this page